Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 2668-2672, November 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pazmiño, N. H.
Right arrow Articles by Yuhas, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pazmiño, N. H.
Right arrow Articles by Yuhas, J. M.

Senescent Loss of Resistance to Murine Sarcoma Virus (Moloney) in the Mouse1

Nelson H. Pazmiño2 and John M. Yuhas

University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences and Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830

Sensitivity to the induction of sarcomas following the injection of the Moloney strain of murine sarcoma virus (MSV-M) has been studied in BALB/c x DBA/2 F1 mice between birth and extreme old age (3 years). In accord with previously published information, we have demonstrated loss of sensitivity, which is at a maximum in newborns, by the time young adulthood is attained. However, sensitivity reappears by 1 year of age and becomes progressively more severe with advancing age. At the oldest ages tested, 2.5 to 3 years, BALB/c x DBA/2 F1 mice are as sensitive as newborns, i.e., 100% develop progressively growing tumors.

This age-dependent sensitivity was reflected by the development of specific neutralizing antibody. The resistant young adults developed a serum antibody which reacted specifically with the virus and which was able to neutralize the oncogenic effects of the MSV-M. Following MSV-M injection, the sensitive newborn and aged mice did not develop this antibody in sufficient concentration to be detected by our tests, nor did mice of any age that were not virus-injected demonstrate this antibody. We propose, therefore, that the age-dependent reappearance of sensitivity to MSV-M results from a similar age-dependent decay of humoral immune capacity.

1 Research supported by the United States Atomic Energy Commission under contract with Union Carbide Corporation.

2 Fellow of the Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela.

Received 5/16/73. Accepted 7/17/73.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.